High Cure Rate with a Moderately Intensive Treatment Regimen in Non-High-Risk Childhood Acute Lymphoblastic Leukemia: Results of Protocol ALL VI from the Dutch Childhood Leukemia Study Group

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 911-918

  Veerman, A J P ^a   Hahlen K ^a   Kamps, W A ^a   Van Leeuwen, E F ^a   De Vaan, G A M ^a   Solbu, G ^a   Suciu, S ^a   Van Wering, E R ^a   Van Der Does Van Den Berg, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; FOLINATE CALCIUM; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SKULL IRRADIATION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKOCYTE COUNT; MALE; METHOTREXATE; NETHERLANDS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0029960017     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.911     Document Type: Article

References (45)

1. Van der Does-Van den Berg A, Van Wering ER, Suciu S, et al: Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: Results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). Am J Pediatr Hematol Oncol 11:125-133, 1989
2. Robison LL, Nesbit ME, Sather HN, et al: Factors associated with IQ scores in long-term survivors of childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 6:115-122, 1984
3. Inati A, Sallan SE, Cassady JR, et al: Efficacy and morbidity of central nervous system 'prophylaxis' in childhood acute lymphoblastic leukemia: Eight years' experience with cranial irradiation and intrathecal methotrexate. Blood 61:297-303, 1983
4. Moe PJ, Seip M, Finne PH: Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Acta Paediatr Scand 70:73-79, 1981
5. Freeman AI, Weinberg V, Brecher ML, et al: Comparison of intermediate dose methotrexate with cranial irradiation for the post induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308:477-483, 1983
6. Komp DM, Fernandez CH, Faletta JM, et al: CNS prophylaxis in acute lymphoblastic leukemia. Comparison of two methods; A Southwest Oncology Group study. Cancer 50:1031-1036, 1982
7. Sullivan MP, Chen T, Dyment PG, et al: Equivalence of intrathecal therapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A Pediatric Oncology Group study. Blood 60:948-958, 1982
8. Jones B, Freeman AI, Shuster J, et al: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-275, 1991
9. Veerman AJP, Hählen K, Kamps WA, et al: Dutch Childhood Leukemia Study group: Early results of study ALL VI (1984-1988). Haematol Blood Transfus 33:473-477, 1990
10. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the classification of the acute leukaemias. Br J Haematol 33:451-459, 1976
11. Bennett JM, Catovsky D, Daniel MT, et al: The French-American-British (FAB) cooperative group: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553-561,1981
12. Catovsky D, Greaves MF, Pain C, et al: Acid-phosphatase reaction in acute lymphoblastic leukaemia. Lancet 1:749-751, 1978
13. Van der Reijden HJ, Van Wering ER, Van de Rijn M, et al: Immunological typing of acute lymphoblastic leukaemia. Scand J Haematol 30:356-366, 1983
14. Van Wering ER, Brederoo P, Van Staalduinen GJ, et al: Contribution of electronmicroscopy to the classification of the minimally differentiated leukemias in children. Recent Results Cancer Res 131:77-87, 1993
15. Smets LA, Homan-Blok J, Hart A, et al: Prognostic implications of hyperdiploidy as based on DNA flow cytometric measurement in childhood acute lymphocytic leukemia - A multicenter study. Leukemia 1:163-166, 1986
16. Hogeman PHG, Veerman AJP, De Waal FC, et al: Handmirror cells in childhood acute lymphoblastic leukemia related to immunological phenotype. Am J Pediatr Hematol/Oncol 7:217-220, 1985
17. Slater RM, Smeets DFCM, Hagemeijer A, et al: Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study group. Haematol Blood Transfus 33:169-173, 1990
18. Veerman AJP, Huismans DR, Van Zantwijk CH: Storage of cerebrospinal fluid samples at room temperature. Acta Cytol 29:188-189, 1985
19. Van Wering ER, Veerman AJP, Van der Linden-Schrever BEM: Diagnosis of meningeal involvement in childhood acute lymphoblastic leukemia: Cytomorphology and TdT. Eur J Haematol 40:250-255, 1988
20. Riehm HJ, Feickert HJ, Schrappe M, et al: for the BFM Study Group. Therapy results in five ALL BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus 30:139-146, 1987
21. Kaplan EL, Meier P: Non parametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Peto J: The calculation and interpretation of survival curves, in Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University, 1984, pp 361-380
23. Breslow N: Comparison of survival curves, in Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University, 1984, pp 381-406
24. Look AT, Roberson PK, Williams DL, et al: Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65:1079-1086, 1985
25. Trueworthy R, Shuster J, Look T, et al: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatrie Oncology Group study. J Clin Oncol 10:606-613, 1992
26. Miller DR, Coccia PF, Bleyer A, et al: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study group. J Clin Oncol 7:1807-1815, 1989
27. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
28. Hryniuk WM, Bertino JR: Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 48:2140-2155, 1969
29. Keefe DA, Capizzi RL, Rudnick SA: Methotrexate cytotoxicity for L5178Y/ASN-lymphoblasts: Relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641-1645, 1982
30. Shapiro WR, Young DF, Mehta BM: Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161-166, 1975
31. Evans WE, Hutson PR, Stewart CF, et al: Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 33:301-307, 1983
32. Wang JJ, Freeman AI, Sinks LF: Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate. Cancer Res 36:1411-1444, 1976
33. Green DM, Brecher ML, Blumenson LE, et al: The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia: A comparison of three versus six courses. Cancer 50:2722-2727, 1982
34. Abromowitch M, Ochs J, Pui C-H, et al: High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Total Therapy Study X. Med Pediatr Oncol 16:297-303, 1988
35. Camitta B, Leventhal B, Lauer S, et al: Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:1539-1544, 1989
36. Camitta B, Mahoney B, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1383-1389, 1994
37. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report. J Clin Oncol 11:520-526, 1993
38. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
39. Balis FM, Lester CM, Chrousos P, et al: Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5:202-207, 1987
40. Kaspers GJL, Pieters R, Zantwijk CH, et al: Childhood acute lymphoblastic leukemia and acute non-lymphoblastic leukemia: Differences in cellular drug resistance, with emphasis on glucocorticoids - A pilot study. Haematol Blood Transfus 35:452-456, 1994
41. Niemeyer CM, Reiter A, Riehm H, et al: Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. Ann Oncol 2:745-749, 1991
42. Clavell LA, Gelber RD, Cohen HJ, et al: Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
43. Smith M: Towards a more uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL), in Gastineau DA, Ramsay NK (eds): ASCO Educational Book. Bostrom Corp, 1994, pp 124-130
44. Pui C-H: Medical progress: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
45. Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61-66, 1991